Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss medication Wegovy. Experts say an oral medication for weight loss might be more cost effective and easier for people to use.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and 5% lower for operating profit than expected, reflects lower GLP-1 penetration in the US market.

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.

Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss drug, Zepbound, delivered stronger results than Wegovy. I

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink analysts say confirm the GLP-1 drug’s edge in the closely watched market race.